ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1764

Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease
Abstract Number: 1765

Persistent Cigarette Smoking Is Associated with Rheumatoid Arthritis Onset and Neutrophil Activation in a Prospective Study of At-risk First-Degree Relatives
Abstract Number: 1766

Inflammatory Priming of the Joints via Pre-activation of Macrophages by Anti-MAA Antibodies in Rheumatoid Arthritis
Abstract Number: 1767

TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts to Induce Inflammation
Abstract Number: 1768

The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study
Abstract Number: 1769

TNF-Stimulated Production of IL-15 by Fibroblast-Like Synoviocytes Mediates Human Resident Memory T Cells Development in Synovial Organoid Model
Abstract Number: 1770

Dual Inhibition of TNF-α and OX40L on Synovial Inflammation and Osteoclastogenesis in Rheumatoid Arthritis
Abstract Number: 1771

Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Abstract Number: 1772

Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients
Abstract Number: 1773

Integrated Analysis of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) Transcriptome and Chromatin Accessibility Identifies Mechanisms Associated with Location-specific Disease Severity
Abstract Number: 1774

Gut Microbiota and Permeability Biomarkers for Diagnosis and Prognosis in Rheumatoid Arthritis Associated Interstitial Lung Disease
Abstract Number: 1775

The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline
Abstract Number: 1776

Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression
Abstract Number: 1777

The Effect of the Inflamed Joint Microenvironment on Endothelial Cell Function
Abstract Number: 1778

Role of GITR/GITRL Interaction in Modulating T Helper 9, T Helper 17 and T Regulatory Response in Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].